MAGNETIC RESONANCE IMAGING OF THE BRAIN IN PATIENTS WITH MULTIPLE SCLEROSIS: TREATMENT WITH IMMUNOMODULATORY DRUGS
https://doi.org/10.29001/2073-8552-2015-30-3-53-57
Abstract
The analysis of the results of immunomodulatory drug-based treatment of multiple sclerosis (MS) with calculation of the volume of tissue damage and the use of magnetic resonance imaging (MRI) at control stages is presented. The article describes the diagnostic MRI criteria of loci of brain tissue damage and their temporal changes in MS during the follow-up period for as long as up to 2 years. The contrast-enhanced study with paramagnetic agent not always enables detection of the presence of MS progression whereas the changes in the number and area of hot spots as well as their migration may be more indicative of worsening of the disease compared with the results of the contrast-enhanced study.
Keywords
магнитно-резонансная томография с контрастным усилением,
рассеянный склероз,
критерии диагностики,
лечение иммуномодуляторами,
количественная оценка динамики очагов,
magnetic resonance imaging,
multiple sclerosis,
diagnostic criteria,
immunomodulators,
follow-up quantification of brain damage
About the Authors
P. I. Lukyanenok
Federal State Budgetary Scientific Institution “Research Institute for Cardiology”
Russian Federation
Russian Federation
V. M. Alifirova
Siberian State Medical University
Russian Federation
Russian Federation
Yu. Yu. Orlova
Siberian State Medical University
Russian Federation
Russian Federation
A. E. Suhareva
Federal State Budgetary Scientific Institution “Research Institute for Cardiology”
Russian Federation
Russian Federation
I. A. Zhukova
Siberian State Medical University
Russian Federation
Russian Federation
T. A. Shelkovnikova
Federal State Budgetary Scientific Institution “Research Institute for Cardiology”
Russian Federation
Russian Federation
W. Yu. Ussov
Federal State Budgetary Scientific Institution “Research Institute for Cardiology”
Russian Federation
Russian Federation
References
1. Алифирова В.М., Титова М.А. Эпидемиологические показатели рассеянного склероза в Томской области и их динамика за последние 30 лет // Бюл. сибирской медицины. - 2012. - Т. 11, № 3. - С. 132-134.
2. Головкин В.И., Поздняков А.В., Камынин Ю.Ф., Мартенс И.С. Новые технологии предикции терапии рассеянного склероза // Бюл. сибирской медицины. - 2010. - № 4. - С. 138-144.
3. Гусев Е.И., Бойко А.Н. Рассеянный склероз: достижения и десятилетия // Журнал неврологии и психиатрии. - 2007. - № 4. - С. 4-13.
4. Завалишин И.А., Захарова М.Н., Бойко А.Н. Рассеянный склероз: основные аспекты патогенеза. Рассеянный склероз и другие демиелинизирующие заболевания. - М. : Миклош, 2004. - С. 60-74.
5. Пажигова З.Б., Карпов С.М., Шевченко П.П., Бурнусус Н.И. Распространенность рассеянного склероза в мире [Электронный ресурс] // Международный журнал экспериментального образования. - 2014. - № 1. - С. 78-82. - URL: www.rae.ru/meo/?section=content&op=show_article&article _id=4560 (дата обращения 20.03.2014).
6. Пати Д.В., Воробейчик Г. Магнитно-резонансная томография при рассеянном склерозе // Журн. невропатологии и психиатрии им. С.С. Корсакова. - 1999. - № 12. - С. 53-57.
7. Фаворова O.O., Кулакова O.Г., Бойко A.Н. Рассеянный склероз как полигенное заболевание: современное состояние проблемы // Генетика. - 2010. - Т. 46, № 3. - С. 302-313.
8. Barkhof F. Comparison of MR imaging criteria at first presentation to predict conversion to clinically definite MS // Brain. - 1997. - Vol. 120. - P. 702-706.
9. Belair M., Girard M. Diagnostic criteria in clinical evaluation of multiple sclerosis: role of magnetic resonance imaging // Can. Assoc. Radiol. J. - 2004. - Vol. 55, No. 1. - P. 29-33.
10. Comi G., Fillippi M., Wolinsky J.S. European/Canadian multicenter double-blind, randomized, placebo-controlled study of the effects of Glatiramer Acetate on Magnetic resonance Imaging-measured disease activity and burden in patients with relapsing multiple sclerosis / European/Canadian Glatiramer Acetate Study Group // Ann. Neurol. - 2001. - Vol. 49. - P. 290-297.
11. Haller S., Pereira V.M., Lalive P.H. et al. Magnetic resonance imaging in multiple sclerosis // Top. Magn. Reson. Imaging. - 2009. - Vol. 20, No. 6. - P. 313-323.
12. Jonson K.P, Brooks B.R., Cohen J.A. Copolymer-1 reduced relapse rate and improved disability in relapsing-remitting multiple sclerosis. Results for a phase III Multicenter, double-blind, placebo-controlled trial // Neurology. - 1998. - Vol. 50. - P. 701-708.
13. Kurtzke J.F. MS epidemiology worldwide. One view of current status // Acta Neurl. Scland. - 1995. - Vol. 91 (suppl. 161). - P. 23-33.
14. Offenbacher H., Fazekas F., Schmidt R. et al. Assessment of MRI criteria for a diagnosis of MS // Neurology. - 1993. - Vol. 43, No. 5. - P. 905-909.
15. PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon 0beta-1a in relapsing-remitting multiple sclerosis // Lancet. - 1998. - Vol. 352. - P. 1498-1504.
16. Tintore E. Isolated demieling syndromes: comparision of different imaging criteria to predict conversion to clinically definite MS // Am. J. Neuroradiology. - 2002. - Vol. 21. - P. 702-706.
Review
For citations:
Lukyanenok P.I., Alifirova V.M., Orlova Yu.Yu., Suhareva A.E., Zhukova I.A., Shelkovnikova T.A., Ussov W.Yu. MAGNETIC RESONANCE IMAGING OF THE BRAIN IN PATIENTS WITH MULTIPLE SCLEROSIS: TREATMENT WITH IMMUNOMODULATORY DRUGS. Siberian Journal of Clinical and Experimental Medicine. 2015;30(3):53-57. (In Russ.) https://doi.org/10.29001/2073-8552-2015-30-3-53-57
Views:
739
.png)
Email this article 